newsfilter
← Latest News
GlobeNewswire·

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

  • Reviva Pharmaceuticals Holdings, Inc. will host a fireside chat & KOL webinar on October 10, 2025, at 11:00 AM ET hosted by A.G.P./Alliance Global Partners.
  • CEO Laxminarayan Bhat, PhD, will participate alongside KOLs Dr. Larry Ereshefsky & Dr. Mark Opler to discuss schizophrenia treatment landscapes.
  • The discussion will cover unmet medical needs for schizophrenia symptoms & phase 3 clinical data for Reviva's lead candidate brilaroxazine.
  • The event will be moderated by James Molloy of A.G.P./Alliance Global Partners.
  • Registration is available via a provided link, & a replay will be accessible in the investor section of Reviva's website post-event.
  • Reviva is a late-stage biopharmaceutical company focused on CNS, inflammatory, & cardiometabolic diseases.
  • Reviva's pipeline includes two in-house discovered new chemical entities: brilaroxazine (RP5063) & RP1208.
  • Reviva holds composition of matter patents for both candidates in the U.S., Europe, & other countries.